Patients with metastatic squamous nsclc. Medical search. Frequent questions

Though Keytruda® and other immunotherapies have yet to be FDA approved for the rare cancer, these therapies have already shown success in various clinical trials in extending survival for numerous patients, including those with classical Hodgkin lymphoma, head and neck squamous cell carcinoma (HNSCC), and certain advanced cancers like melanoma and metastatic urothelial carcinoma. (mesothelioma.com)
It is also used to treat metastatic squamous non-small cell lung cancer with progression with or after platinum-based drugs and for treatment of small cell lung cancer It also used as a second-line treatment for renal cell carcinoma after anti-angiogenic treatment has failed. (wikipedia.org)
Nivolumab is used for primary or metastatic urothelial carcinoma, the most common form of bladder cancer. (wikipedia.org)
In May 2022, the U.S. FDA expanded the indication to include the first-line treatment of patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). (wikipedia.org)
KEYTRUDA, Merck's anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma (HCC) who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) compared with placebo plus best supportive care. (merck.com)
KEYTRUDA monotherapy is already playing a role for the treatment of certain patients with advanced endometrial carcinoma through the tumor-agnostic MSI-H indication which received accelerated approval four years ago. (businesswire.com)
KEYTRUDA was also granted accelerated approval in September 2019, and received full approval in July 2021, in combination with LENVIMA ® (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. (businesswire.com)
KEYNOTE-158 (ClinicalTrials.gov, NCT02628067 ) is an ongoing global, open-label, non-randomized, multi-cohort, multi-center, Phase 2 study evaluating KEYTRUDA in patients with multiple types of advanced solid tumors - including endometrial carcinoma - that have progressed on standard of care therapy. (businesswire.com)
Cohort K enrolled 79 patients with MSI-H endometrial carcinoma and Cohort D enrolled 11 patients with MSI-H endometrial carcinoma for a total of 90 pooled patients who received KEYTRUDA as monotherapy (200 mg fixed dose every three weeks). (businesswire.com)
Pembrolizumab (Keytruda), a humanized monoclonal anti-PD-1 antibody, is the first anti-PD-1 antibody approved by the FDA for the treatment of patients with unresectable or metastatic melanoma, non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, and gastric/gastroesophageal junction cancer [ 4 - 10 ]. (hindawi.com)
The drug's sales are growing from continued strong momentum in metastatic indications, including some types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma cancers, and a rapid uptake across recent earlier-stage launches. (zacks.com)
We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. (frontiersin.org)
Approximately 80-90% of newly diagnosed lung cancers are classified as NSCLC, primarily consisting of adenocarcinoma, squamous cell carcinoma, or large cell carcinoma histologies. (frontiersin.org)
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. (medscape.org)
It is being developed based on OmniRat transgenic animal platform.Sugemalimab (Cejemly) is under development for the treatment of solid tumors including endometrial cancer, cholangiocarcinoma, recurrent head and neck squamous cell carcinoma (HNSCC). (globaldata.com)
MGC018 is currently being evaluated in a Phase 1/2 dose expansion study in patients with metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN) and melanoma. (macrogenics.com)
patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). (tacomavetmedication.com)
Immune checkpoint inhibitor Keytruda (pembrolizumab) did not significantly improve the survival outcomes of previously treated hepatocellular carcinoma patients on best supportive care, results from a Phase 3 trial show. (immuno-oncologynews.com)
This study will test whether vaccination with viagenpumatucel-L combined with strategies to modulate the immune response is safe for patients with non-small cell lung adenocarcinoma or squamous cell carcinoma for incurable or metastatic disease. (mycancergenome.org)
Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. (kdvr.com)
risk of esophageal squamous cell carcinoma. (who.int)
PMID:18786442 mutations and the risk of esophageal squamous cell carcinoma. (who.int)
Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch squamous cell carcinoma in a high-risk region in Iran. (who.int)

The data support the combination of pembrolizumab and chemotherapy as a ﬁrst-line treat-ment for metastatic squamous NSCLC in patients with PD-L1‒positive and PD-L1‒negative tumors. (bpno.no)
GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , Clinical Studies (14.1) ]. (nih.gov)
It is estimated approximately 5-15% of colorectal cancer patients have tumors that score as either MSI-H or dMMR when testing is performed. (merck.com)
KEYTRUDA is approved for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (businesswire.com)
Cite this: TLS in Tumors May Predict Immunotherapy Benefit in NSCLC - Medscape - Nov 10, 2023. (medscape.com)
Treating the brain with a preventative course of radiation may help Small Cell Lung Cancer (SCLC) patients - whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. (news-medical.net)
New research shows that current approaches to genome analysis systematically miss detecting a certain type of complex mutation in cancer patients' tumors. (news-medical.net)
NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: preliminary phase 1/2 results of PIVOT. (medscape.org)
Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. (medscape.org)
Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced solid tumors or lymphomas. (medscape.org)
KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. (pipelinereview.com)
The TROP-2-directed antibody-drug conjugate datopotamab deruxtecan may significantly improve progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), especially in patients with non-squamous cell tumors, according to new findings simultaneously published by Ahn et. (ascopost.com)
MacroGenics is also evaluating the activity of MGC018 plus lorigerlimab (an investigational PD-1 × CTLA-4 bispecific DART ® molecule) in a Phase 1 study in patients with advanced solid tumors. (macrogenics.com)
However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. (biomedcentral.com)
Stereotactic body radiotherapy (SBRT) may be used in early-stage NSCLC tumors that are smaller than 5 cm without lymph node involvement. (medscape.com)

Nivolumab is indicated for the adjuvant treatment of people with melanoma with involvement of lymph nodes or in people with metastatic disease who have undergone complete resection. (wikipedia.org)
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma. (merck.com)
Efficacy of BMS-986016 (relatlimab), a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in patients with melanoma who progressed during prior anti-PD-1/PD-L1 therapy in all-comer and biomarker-enriched populations. (medscape.org)
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. (medscape.org)
A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. (medscape.org)
KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. (pipelinereview.com)
unresectable or metastatic melanoma. (tacomavetmedication.com)

Mutations in epidermal growth factor receptor ( EGFR ), KRAS, and anaplastic lymphoma kinase ( ALK ) are mutually exclusive in patients with NSCLC, and the presence of one mutation in lieu of another can influence response to targeted therapy. (medscape.com)
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). (news-medical.net)
This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. (news-medical.net)
The treatment of patients with epidermal growth factor receptor (EGFR)-mutated lung cancer that progresses on EGFR-targeted tyrosine kinase inhibitors has been challenging. (ascopost.com)

The study revealed that combining pembrolizumab with chemo-therapy in patients with previously untreated metastatic squamous NSCLC improved OS, PFS, and PFS-2, increased ORR, and longer duration of respons than placebo plus chemotherapy. (bpno.no)
Eligible patients with previously untreated, metastatic squamous non-small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and paclitaxel/nab-paclitaxel once every 3 weeks for four cycles, followed by pembrolizumab or placebo for up to 35 cycles. (nih.gov)
Pembrolizumab plus chemotherapy maintained an OS and PFS benefit versus placebo plus chemotherapy in previously untreated, metastatic squamous NSCLC and is a standard-of-care first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression. (nih.gov)
Pembrolizumab ( Keytruda ) was granted accelerated approval by the FDA in combination with pemetrexed and carboplatin to treat patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). (pharmacytimes.com)
Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses new phase III findings from the CheckMate 77T trial of patients with previously untreated resectable stage II-IIIB non-small cell lung cancer (NSCLC). (ascopost.com)

The positive results from KEYNOTE-407 correlate to a previous study that focused on another type of lung cancer, metastatic nonsquamous NSCLC. (mesothelioma.com)
The team analyzed samples from patients in the IMpower110 phase 3 study, which compared first-line atezolizumab vs chemotherapy in patients with metastatic nonsquamous or squamous NSCLC and PD-L1 expression of 1% or higher. (medscape.com)
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. (news-medical.net)
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. (pipelinereview.com)
Cejemly in combination with pemetrexed and carboplatin is indicated as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations and in combination with paclitaxel and carboplatin as first-line treatment of patients with metastatic squamous NSCLC. (globaldata.com)

The monoclonal antibody is currently cleared by the FDA to treat people with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumour has ALK and EGFR mutations. (pharmatimes.com)
[ 4 ] Further investigation demonstrated that the highest response rates to these TKIs were seen in patients with somatic mutations within the EGFR-TK domain, particularly exon 19 deletion, exon 21 L858R, and exon 18 G719X. (medscape.com)
In general, activating EGFR mutations are more commonly observed in patients with adenocarcinomas and no prior history of smoking, as well as in females and those of Asian descent. (medscape.com)
Use of the EGFR-TKIs gefitinib, erlotinib, and afatinib is limited to patients with adenocarcinomas who have known activating EGFR mutations. (medscape.com)
[ 9 ] Most importantly, patients with KRAS mutations seem to have a poorer prognosis and seem to be resistant to EGFR-TKIs, although the extent to which this might influence treatment selection remains somewhat unclear. (medscape.com)
Because EGFR and ALK mutations are mutually exclusive, patients with ALK rearrangements are not thought to benefit from EGFR-targeting TKIs. (medscape.com)
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. (pipelinereview.com)
Third, the BEVERLY trial showed that the combination of Erlotinib with Bevacizumab in advanced EGFR-mutated NSCLC prooved to be superior to Erlotinib monotherapy in the current/former smoker subgroup, suggesting that this subgroup represents a differnt tumor biology with sprecial therapeutic needs. (springermedizin.at)
Across the cohorts, 104 patients were EGFR mutation positive and had an ALK rearrangement. (esmo.org)
The co-primary endpoints were investigator-assessed progression-free survival (PFS) and OS in the in the intent-to-treat (ITT) EGFR/ALK wild-type population and PFS in patients with a T-effector (T-eff) signature. (esmo.org)
95% CI 0.49,1.37) for patients with liver metastases and EGFR/ALK alterations, respectively. (esmo.org)
Ivonescimab had an acceptable safety profile in combination with platinum-doublet chemotherapy for patients with advanced or metastatic NSCLC who had progressed following an EGFR-TKI, as well as in combination with chemotherapy for patients who had progressed following treatment with a PD-(L)1 inhibitor plus platinum-doublet chemotherapy in this clinical study. (starkvilledailynews.com)
HARMONi intends to evaluate ivonescimab combined with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) (AK112-301, NCT05184712). (starkvilledailynews.com)
Patients with EGFR activating mutations or ALK- positive tumour mutations should also have received targeted therapy (i.e. (who.int)
ALK /EGFR-TKIs) before receiving atezolizumab (Cohort 2 LOT2+ NSCLC). (who.int)

The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established. (businesswire.com)
ROS-1 gene alterations, thought to lead to abnormal cells, have been identified in various cancers, including NSCLC. (medscape.com)
Lung cancers are histologically classified as Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC). (frontiersin.org)
Our vision for the future of cancer care is focused on researching and developing transformational medicines, including Immuno-Oncology (I-O) therapeutic approaches, for hard-to-treat cancers that could potentially improve outcomes for these patients. (bms.com)
Our differentiated clinical development program is studying broad patient populations across more than 50 types of cancers with 24 clinical-stage molecules designed to target different immune system pathways. (bms.com)
These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. (biomedcentral.com)
Clinical activity of TIL therapy has also been reported in other cancer types, including human papillomavirus-associated cancers, cholangiocarcinoma, non-small-cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). (biomedcentral.com)

Consequently, the CRL stated that Merck's and Eisai's applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. (pipelinereview.com)

Background To date, none of randomised trials aim to compare the efficacy of programmed death 1 (PD-1) inhibitor plus chemotherapy and bevacizumab plus chemotherapy as first-line treatment for non-squamous non-small-cell lung cancer (NSCLC). (bmj.com)
Conclusions PD-1 inhibitor plus chemotherapy was associated with significant survival benefits compared with bevacizumab plus chemotherapy in patients with advanced non-squamous NSCLC, which provides evidence support to guide clinical practice. (bmj.com)
AK112-201 (NCT04736823) is an open-label Phase II study evaluating ivonescimab plus chemotherapy for 174 patents across three cohorts of patients. (starkvilledailynews.com)

Among patients with TLS in tumor tissues, those who received atezolizumab demonstrated the greatest overall survival benefit compared with those who received chemotherapy, according to research presented at the 2023 annual meeting of the Society for Immunotherapy of Cancer (SITC). (medscape.com)
In May 2023, the first patient in Summit's license territories was treated in the Phase III HARMONi clinical trial. (biotech-365.com)
Summit intends to dose patients in the HARMONi-3 trial during the second half of 2023. (biotech-365.com)

In addition to the reduction of severe oral mucositis, an acceleration in the clearance of tumor response and an increase in overall survival were also observed in the Phase 2 clinical study as an ancillary benefit to treating oral mucositis in patients receiving chemo-radiation for their head and neck cancer. (constantcontact.com)
Previous studies have shown that nutritional counseling is able to increase protein-calorie intake, prevent the deterioration of nutritional status and quality of life (QoL) in patients with head-and-neck (H&N) cancer [ 5 ]. (biomedcentral.com)

The decision comes after pembrolizumab, in combination with platinum-based doublet chemotherapy, was associated with a progression-free survival and overall survival benefit over platinum-based doublet chemotherapy in patients with treatment naïve metastatic squamous NSCLC. (roycastle.org)
The anti-PD-L1 antibody, atezolizumab administered together with bevacizumab , carboplatin , and paclitaxel reduced the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non-small cell lung cancer (NSCLC), according to findings presented at the ASCO 2018 Annual Meeting, held 1 to 5 June in Chicago, USA. (esmo.org)
CheckMate -331 is an open-label, randomized Phase 3 study evaluating Opdivo monotherapy versus chemotherapy in patients with relapsed small cell lung cancer (SCLC) following platinum-based chemotherapy. (bms.com)

The study's data concluded that the combination of Keytruda® (pembrolizumab) and standard platinum-based chemotherapy should be the new first-line treatment for metastatic non-small cell lung cancer (NSCLC), which could also mean changes ahead for mesothelioma treatment . (mesothelioma.com)
It means that, for the first time, patients across the UK with this form of lung cancer will have access to pembrolizumab in combination with chemotherapy, rather than having to wait to finish a course of chemotherapy. (roycastle.org)
This decision makes pembrolizumab, which also has the trade name Keytruda, the first immunotherapy to be approved for use as a first line treatment, in combination with chemotherapies carboplatin and either paclitaxel or nab-paclitaxel, for patients in Scotland with metastatic squamous non-small cell lung cancer (NSCLC) in adults. (roycastle.org)
The SMC has accepted pembrolizumab in combination with chemotherapy for the initial treatment of metastatic squamous NSCLC in adults. (roycastle.org)
The distribution of grade 3-4 neurologic ir-AEs frequency was 0.7% among patients receiving anti-CTLA-4 (ipilimumab and tremelimumab), 0.4% among patients receiving anti-PD1 (nivolumab, pembrolizumab, lambrolizumab, and pidilizumab), and 0.7% among patients receiving a combination therapy (anti-CTLA-4 + anti-PD1) [ 20 ]. (hindawi.com)
The results of the study showed an improvement in overall response rate (ORR) and in progression-free survival (PFS) for patients administered pembrolizumab plus PC. (pharmacytimes.com)
Ninety-three percent of patients who had a response that lasted 6 months or longer in the pembrolizumab arm and 81% in the PC alone arm, according to the release. (pharmacytimes.com)
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. (medscape.org)
In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. (ascopost.com)
OBJECTIVE: The effectiveness of pembrolizumab for persistent, recurrent, or metastatic cervical cancer has been demonstrated. (bvsalud.org)
RESULTS: For the Intention-to-Treat patients, pembrolizumab was associated with an additional 0.74 quality-adjusted life-year (QALY) at an additional cost of $182,271 when compared with placebo. (bvsalud.org)
CONCLUSION: The addition of pembrolizumab to chemotherapy is costly and might not be cost-effective for persistent, recurrent, or metastatic cervical cancer at the current price in the US. (bvsalud.org)
Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab ± pemetrexed every 3 weeks. (mycancergenome.org)

In arm A, maintenance therapy was given with atezolizumab alone and in arm B patients received maintenance therapy with the combination of bevacizumab and atezolizumab. (esmo.org)
466 patients received PD-1 inhibitor (200 mg) plus pemetrexed (500 mg/m²) and platinum (cisplatin 75 mg/m 2 or carboplatin area under the curve (AUC) 5 mg/mL/min), while 432 patients received bevacizumab (15 mg/kg) plus paclitaxel (175 mg/m 2 ) and carboplatin (AUC 6 mg/mL/min). (bmj.com)
o In combination with bevacizumab, paclitaxel and carboplatin for the first line treatment of adult patients with metastatic non-squamous NSCLC. (who.int)

Researchers found that with just the standard chemotherapy combination of carboplatin and paclitaxel/nab-paclitaxel, median overall survival for metastatic NSCLC reached about 11.3 months. (mesothelioma.com)
Avastin, in combination with carboplatin and paclitaxel, is indicated for the first‑line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer. (avastin.com)
Our Phase III results showed Tecentriq in combination with Avastin, paclitaxel and carboplatin has the potential to provide a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer," said Sandra Horning, Roche's chief medical officer and head of Global Product Development. (pharmatimes.com)
Continued exposure to afatinib plus paclitaxel can benefit non-small-cell lung cancer patients who developed resistance to erlotinib or gefitinib and progressed after initially responding to afatinib monotherapy, suggest phase III trial results. (news-medical.net)
IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. (medscape.org)
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC. (pipelinereview.com)
Objective: To assess the cost-effectiveness of atezolizumab in combination with carboplatin plus nab-paclitaxel-based chemotherapy versus chemotherapy alone for first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) from the Chinese healthcare system perspective.Methods: A Markov model was developed based on the IMpower130 clinical trial. (bvsalud.org)
In May 2022, the supplemental new drug application ("sNDA") for toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic ESCC was approved by the NMPA in China. (itbusinessnet.com)
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization. (kdvr.com)

When they paired chemotherapy with Keytruda®, follow-ups showed overall survival extended to 15.9 months on average across all the lung cancer patient subgroups in the trial, including in those with low PD-L1 expression. (mesothelioma.com)
Researchers found adding Keytruda® to the conventional chemotherapy regime significantly increased life expectancy for patients with this type of lung cancer, as well. (mesothelioma.com)
As monotherapy in second-line HCC, in addition to KEYNOTE-240 and KEYNOTE-224, KEYTRUDA is being investigated in the ongoing Phase 3, KEYNOTE-394 trial, a randomized, double-blind trial evaluating KEYTRUDA in combination with best supportive care, compared to placebo in combination with best supportive care, in Asian patients with advanced HCC who were previously treated with systemic therapy. (merck.com)
ClinicalTrials.gov, NCT02702401 ) evaluating KEYTRUDA plus best supportive care compared to placebo plus best supportive care in patients with advanced HCC who were previously treated with systemic therapy. (merck.com)
The study enrolled 413 patients who were randomized to receive either KEYTRUDA (200 mg fixed dose every three weeks for up to 35 cycles of treatment [up to approximately two years]) plus best supportive care (including pain management and management of other potential complications including ascites per local standards of care) or placebo plus best supportive care. (merck.com)
This positive EU CHMP opinion reinforces the potential of KEYTRUDA as a new option for patients with MSI-H/dMMR colorectal cancer and illustrates our ongoing commitment to pursuing biomarker research to help address the needs of patients who have few effective options. (merck.com)
MRK ), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer. (streetinsider.com)
At the study's final analysis, there was not an improvement in OS for patients treated with KEYTRUDA plus LENVIMA with chemotherapy compared to KEYTRUDA with chemotherapy. (streetinsider.com)
As a leader in lung cancer research, we continue to try to advance science for our patients by building upon the standard we set several years ago with KEYTRUDA," said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck Research Laboratories. (streetinsider.com)
While these results are not what we hoped for, we are proud of the foundational role that KEYTRUDA has established in the treatment of certain types of lung cancer, and we are committed to continuing to research how we can further improve responses to our medicines for patients with difficult-to-treat forms of the disease. (streetinsider.com)
Keytruda improved overall response rate and progression free survival in NSCLC. (pharmacytimes.com)
MRK - Free Report ) Keytruda for late-stage NSCLC patients who have progressed after Keytruda treatment. (zacks.com)

The presence of tertiary lymphoid structures (TLS) in tumor tissues may predict the patients with advanced non-small cell lung cancer (NSCLC) who will benefit most from treatment with atezolizumab (Tecentriq), new findings suggest. (medscape.com)
This exploratory analysis indicates that "the presence of TLS in tumor tissues may identify a subset of patients that benefits from atezolizumab monotherapy in the PD-L1-intermediate or low population," the study authors, led by Barzin Nabet, PhD, a principal scientist with Genentech's Oncology Biomarker Development sector, explained. (medscape.com)
An analysis of data from the phase 2 POPLAR trial, for instance, found that the presence of TLS was strongly associated with an overall survival benefit among previously treated patients who received atezolizumab or chemotherapy. (medscape.com)
First, neoadjuvant Atezolizumab managed to show a superior DFS compared to best supportive care in completely resected NSCLC stage II-IIIA. (springermedizin.at)
Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. (springermedizin.at)
IMpower010: characterization of stage IB-IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. (springermedizin.at)
IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. (springermedizin.at)
A total of 45 patients treated with second-line single-agent CIT (ie, atezolizumab or otherwise) for advanced or metastatic NSCLC, as well as HCPs, whose exact number was decided by the clinics, were recruited from 10 clinics in Germany, Finland, and Switzerland between February and May 2019. (jmir.org)
4. Patients not receiving atezolizumab, but a biosimilar or non-original biologic. (who.int)

The most recent 1 presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, by Dr Alexander Drilon, looked at selpercatinib and reported out the data in all patients, so patients who had not gotten any prior treatments, treatment-naïve patients, as well as just a broader group of patients. (onclive.com)
The impact is the same that in other molecular selected non-small cell lung cancer patients, such as ROS1 or ALK rearranged in NLCLC [non-small cell lung cancer]. (onclive.com)
March 3, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) today announced three research projects selected to receive funding to improve healthcare provider performance and/or healthcare quality, focusing on enhancing patient care and outcomes for people with advanced non-small cell lung cancer (NSCLC). (biospace.com)
US regulators are undertaking a priority review of Roche unit Genentech's PD-L1 inhibitor Tecentriq, in combination with Avastin and standard chemotherapy for some patients with lung cancer. (pharmatimes.com)
The application is seeking permission to market the combination for the first-line treatment of patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). (pharmatimes.com)
Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small molecules that target genetic mutations known to play critical roles in the progression to metastatic disease. (medscape.com)
Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. (news-medical.net)
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. (news-medical.net)
The biologic was submitted for regulatory approval in 2013 based on data from the REGARD trial, and due to the success of the biologic in the RAINBOW trial, Lilly plans to submit ramucirumab in combination with chemotherapy for patients with non-small cell lung cancer (NSCLC) later in 2014. (pm360online.com)
AZN - Free Report ) Tagrisso (osimertinib) for patients with late-stage non-small cell lung cancer (NSCLC). (zacks.com)
Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). (frontiersin.org)
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiation, chemotherapy, and surgery in certain individualized cases. (frontiersin.org)
Stage III lung cancer, though heterogeneous in its classification, includes non-metastatic but locally advanced disease with involvement of N1-N3 nodal stations and/or T3 and T4 primaries. (frontiersin.org)
Presently, stage III lung cancer is managed with a combination of chemotherapy, radiation therapy, and sometimes surgery but the two major challenges in improving outcomes of the treatment of this disease remain local control and metastatic spread. (frontiersin.org)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. (medscape.org)
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. (medscape.org)
Nutritional support, including nutritional counseling and oral nutritional supplements (ONS), has been recommended as a first-line strategy in patients with non-small cell lung cancer (NSCLC). (biomedcentral.com)
Since diagnosis, patients with non-small cell lung cancer (NSCLC) frequently present a variable impairment of nutritional status. (biomedcentral.com)
Cejemly is indicated for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy. (globaldata.com)
Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). (springermedizin.at)
Intensity-modulated radiation therapy (IMRT) reduced the risk of toxicity to the lungs and radiation exposure to the heart vs three-dimensional conformal radiotherapy (3D-CRT) for the treatment of locally advanced non-small cell lung cancer (NSCLC), according to a planned long-term prospective. (ascopost.com)
Early-phase trials demonstrate the potential for TROP-2-directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International. (ascopost.com)
Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy-given before and after surgery-significantly improved event-free survival in patients with resectable early-stage non-small cell lung cancer (NSCLC). (ascopost.com)
The combination of the ATR inhibitor ceralasertib and the immune checkpoint inhibitor durvalumab has demonstrated notable survival rates and clinical benefits among patients who have advanced non-small cell lung cancer (NSCLC) with RAS mutations, according to data presented at the International. (ascopost.com)
In a phase II trial reported in JAMA Oncology, Takahashi et al found that the addition of the ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor berzosertib to topotecan did not improve progression-free survival in patients with relapsed small cell lung cancer (SCLC). (ascopost.com)
Complete surgical resection is the treatment of choice for operable early-stage non-small cell lung cancer (NSCLC) and resectable stage IIIA. (ascopost.com)
On October 11, the U.S. Food and Drug Administration (FDA) approved the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) for adult patients with metastatic non-small cell lung cancer (NSCLC) and a BRAF V600E mutation, as detected by an FDA-approved test. (ascopost.com)
This clinical study is for patients with advanced non-small cell lung cancer (NSCLC). (clinicaltrialsregister.eu)
Cancer immunotherapy (CIT), as a monotherapy or in combination with chemotherapy, has been shown to extend overall survival in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). (jmir.org)
PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. (bms.com)
We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. (bms.com)
Surgery is recommended for patients with stage I or II non-small cell lung cancer NSCLC) and may provide the best possibility for a cure. (medscape.com)
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer (NSCLC) patients have been under debate for many years. (sense-studios.com)
An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683. (sense-studios.com)
Patients diagnosed with locally advanced/metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. (who.int)

Analyses of ORR were conducted in subgroups of patients with PD-L1 tumor expression, according to the release. (pharmacytimes.com)
Multiple studies have examined the issue of the optimal dose of radiotherapy in NSCLC but are complicated by the heterogeneity of the disease itself in terms of size and location of the primary tumor, number and size of involved lymph nodes, and the patient's comorbidities, all of which limit the treatment tolerability and risks. (frontiersin.org)
Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with chemotherapy and radiotherapy. (itbusinessnet.com)
Immunosuppression hinders that response, and may develop in NSCLC patients in a variety of ways, such as activation of checkpoint pathways in the tumor microenvironment. (mycancergenome.org)
One is the ability to administer large numbers of highly selected cells with high avidity for tumor antigens that can recognize shared and patient-specific mutated (neo) antigens. (biomedcentral.com)
Cohort 3: Advanced or metastatic NSCLC patients whose tumor has progressed following PD-(L)1 therapy combined with doublet-platinum chemotherapy. (starkvilledailynews.com)
the decision to treat the patient with concurrent chemoradiation rather than surgery, radiation, or chemotherapy individually should be made by a multidisciplinary tumor board (including a medical oncologist, radiation therapist, and thoracic surgeon). (medscape.com)

Toady if you want to treat a RET -positive and ALK patient, you will use either platinum-based chemotherapy or multikinase inhibitor. (onclive.com)
A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center. (news-medical.net)
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. (medscape.org)
The Company plans to initiate the Phase 2 portion of the TAMARACK Phase 2/3 study in patients with mCRPC who have had prior exposure to a taxane and at least one androgen receptor axis-targeted, or ARAT, agent (including abiraterone, enzalutamide or apalutimide), and a PARP (poly adenosine diphosphate-ribose polymerase) inhibitor, if appropriate. (macrogenics.com)

In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. (news-medical.net)
Median PFS experienced by these patients was 12.3 months (95% CI: 8.3 to 19.3 months) and median overall survival was not reached after 13.3 months of median follow-up time. (starkvilledailynews.com)

The first HER2-directed therapy (ie, trastuzumab deruxtecan ) received accelerated approval from the FDA for NSCLC in August 2022. (medscape.com)
As we look back at the policy challenges of 2021 on both the State and federal levels and in anticipation of similar challenges in 2022, BioNJ is laser focused and committed to working with policymakers to implement solutions that ensure Patients have meaningful access to their medicines, reduce health care costs and support innovation necessary for future cures and treatments. (constantcontact.com)
Sugemalimab has been approved in China for the treatment of patients with stage III NSCLC and recommended by 2022 Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Primary NSCLC as a preferred treatment option. (cstonepharma.com)

We aimed to describe the treatment quality, resource-driven adaptations, and outcomes of cervical cancer patients in Rwanda. (bvsalud.org)
METHODS: A retrospective cohort study was conducted of all patients with newly diagnosed cervical cancer enrolled between April 2016 and June 2018. (bvsalud.org)

The safety profile of Opdivo in this trial was consistent with that observed in previously reported monotherapy studies involving patients with SCLC. (bms.com)
As part of this program, the Company is investigating the role of Opdivo plus Yervoy and Opdivo monotherapy versus placebo in the frontline setting as a maintenance therapy for patients with SCLC who do not progress on first-line chemotherapy. (bms.com)
After 18 weeks of treatment , patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. (mycancergenome.org)
o As monotherapy for the treatment of adult patients with locally advanced/metastatic UC after prior platinum-containing chemotherapy (Cohort 1 LOT2+ mUC). (who.int)

[ 9 , 10 ] KRAS G12C accounts for approximately 50% of KRAS mutations in NSCLC, and approximately 14% of patients with NSCLC have a KRAS G12C mutation. (medscape.com)
Further, a significant percentage of these complex mutations are found in well-known cancer genes that could be targeted by existing drugs, potentially expanding the number of cancer patients who may benefit. (news-medical.net)
This analysis pooled prospective data to compare the survival benefits of the two regimens for advanced NSCLC without targetable genetic mutations. (bmj.com)

In April 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab, in combination with certain types of chemotherapy, for the initial treatment of people with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. (wikipedia.org)
Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. (mycancergenome.org)
After the completion of 18 weeks of combination therapy , patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion. (mycancergenome.org)

The approval was based on findings from the multicenter, multi-cohort KEYNOTE-021 study, which included 123 treatment-naive patients with locally advanced or metastatic non-squamous NSCLC. (pharmacytimes.com)

Patients in Europe with MSI-H/dMMR colorectal cancer have had only chemotherapy-containing regimens available to them in the first-line treatment setting and have historically faced poor outcomes," said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. (merck.com)

However, exploratory subgroup analysis indicated that median PFS and median OS of the two arms were comparable in patients with negative programmed death ligand 1 expression or in patients aged ≥65 years old. (bmj.com)
For patients with a programmed death-ligand 1 combined positive score ≥ 1 and 10, the ICER was $253,322/QALY and $214,212/QALY, respectively. (bvsalud.org)

These projects will hopefully serve as sustainable models for promoting system efficiency and enhancing patient outcomes and satisfaction. (biospace.com)
Immunonutrition represents a promising approach also in patients with NSCLC, but evidence on its efficacy on clinical outcomes during immunotherapy is still inconclusive. (biomedcentral.com)
The discovery and development of novel treatments that harness the patient's immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. (biomedcentral.com)
The clinical success of immune checkpoint inhibitors has dramatically changed outcomes for patients across cancer types. (biomedcentral.com)

In unresectable NSCLC, chemoradiation has been the standard of care for the past three decades. (frontiersin.org)
More recently, phase I/II studies using SBRT for dose escalation after conventional chemoradiation in locally advanced NSCLC have been promising with good apparent safety. (frontiersin.org)
By building on the proven concept of conventional chemoradiation for patients with locally advanced NSCLC with a subsequent radiation dose intensification to residual disease with SBRT concurrent with immunotherapy, we hope address the issues of metastatic and local failures. (frontiersin.org)
Of 254 patients added to a waiting list for chemoradiation, 114 ultimately received chemoradiation. (bvsalud.org)

Second, Cemiplimab combined with chemotherapy reached the primary endpoint of OS compared to chemo alone in advanced stage IIIB/C & stage IV NSCLC patients. (springermedizin.at)
Summit has begun clinical development activities on the Phase III HARMONi-3 study, which intends to evaluate ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients. (starkvilledailynews.com)

It showed overall increased survival as a first-line treatment for patients with stage IV metastatic NSCLC, when taken in combination with chemotherapy. (pm360online.com)
From the time of diagnosis, the median range of survival for extensive-stage SCLC (ES-SCLC) patients is between eight and 13 months. (bms.com)

Histology information was not available for 1 patient in the Avastin + PC arm. (avastin.com)
Notably, this Phase II data set summarizes results to date from 63 patients with squamous histology. (starkvilledailynews.com)
In addition to the patients with squamous histology described above, Cohort 1 includes updated data from 72 patients with non-squamous histology. (starkvilledailynews.com)

The prospective phase 3 LungART trial now demonstrated that PORT cannot be recommended as a standard of care in all completely resected stage IIIA N2 NSCLC patients [1]. (sense-studios.com)
To evaluate the value of PORT in completely resected stage IIIA N2 NSCLC patients, the phase 3 LungART trial was developed. (sense-studios.com)
Therefore, PORT cannot be recommended as a standard of care in all completely resected stage IIIA N2 NSCLC patients. (sense-studios.com)

It can be prescribed for locally advanced or metastatic form of the condition that experience disease progression during or following platinum-containing chemotherapy or have progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (wikipedia.org)
And an encouraging thing actually is that none of the patients had progression at this point on the targeted therapy. (onclive.com)

The combination of Reqorsa and Tagrisso has received Fast Track Designation from the FDA for treating the Acclaim-1 patient population. (zacks.com)

We profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. (frontiersin.org)

adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy. (tacomavetmedication.com)

Many advanced NSCLC clinical trials are also often applied to mesothelioma, as the disease progressions are rather similar. (mesothelioma.com)
The incidence rate for any grade ICIs-related neurologic ir-AEs in patients included in clinical trials has been reported to be approximately 3.8% to 12% [ 20 ]. (hindawi.com)
Notably, in the JCAR015 Phase 2 Clinical Trial (ROCKET) conducted by Juno Therapeutics, five patients died because of severe cerebral edema, causing the cessation of clinical trials by the FDA [ 22 ]. (hindawi.com)
Local and distant failure remains high in this group of patients, so dose escalation has been studied in both single institution and national clinical trials. (frontiersin.org)

Additionally, US FDA has also granted an orphan drug designation to toripalimab for the treatment of patients with ESCC. (itbusinessnet.com)

Baseline liver metastases were present in 94 patients. (esmo.org)
Numerous patients with OS as of now have progressed illness with far off metastases at the hour of beginning show, and in this manner it presents incredible difficulties to clinical specialists. (hilarispublisher.com)

One patient in the Avastin plus PC arm was missing in the evaluation of histologies. (avastin.com)

Evidence on the efficacy of immunonutrition during immunotherapy in these patients is positive, but still limited some secondary endpoints, such as treatment toxicity and tolerance. (biomedcentral.com)
We hypothesize that early systematic provision of ONS with a high-protein-high calorie mixture containing immunonutrients (Impact®) in addition to nutritional counseling, compared to nutritional counseling alone, is beneficial to patients with NSCLC receiving immunotherapy with or without chemotherapy. (biomedcentral.com)
We designed the present study to evaluate the efficacy of early systematic provision of ONS enriched with immunonutrients compared to nutritional counseling alone, in patients with NSCLC undergoing immunotherapy. (biomedcentral.com)
The present pilot study, which guarantees early high-quality nutritional care (assessment and treatment) to all patients in agreement with current guidelines and recommendations, could represent one of the first proofs of efficacy of early oral immunonutrition in patients with cancer undergoing immunotherapy. (biomedcentral.com)

Now we want to make it easier for medical practices to implement these innovations and make sure they're reaching every patient who could benefit from them. (biospace.com)
We understand making the promise of transformational medicines like I-O therapies a reality for the many patients who may benefit from these therapies requires not only innovation on our part but also close collaboration with leading experts in the field. (bms.com)

Surgery (radiation if the patient is not a surgical candidate), with or without adjuvant chemotherapy based on risk factors, for stages IB and II is generally appropriate. (medscape.com)

Forty percent of these patients present with locally advanced disease ( 3 ). (frontiersin.org)

Anatomy8

Organisms2

Diseases23

Chemicals and Drugs88

Analytical, Diagnostic and Therapeutic Techniques and Equipment86

Psychiatry and Psychology1

Phenomena and Processes45

Disciplines and Occupations3

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science6

Named Groups1

Health Care31

Geographicals1

Carcinoma23

Tumors15

Melanoma7

Epidermal growth f4

Previously untreated5

Nonsquamous5

EGFR15

Cancers7

Unresectable or metastatic1

Plus chemotherapy3

20233

Head and neck2

Chemotherapy in patients3

Pembrolizumab13

Bevacizumab3

Paclitaxel9

Keytruda12

Atezolizumab9

Lung35

Tumor7

Inhibitor4

Overall survival2

20223

Cervical cancer2

Monotherapy4

Mutations3

Nivolumab3

Treatment-naive1

Colorectal cancer1

Death ligand2

Outcomes4

Chemoradiation4

Combined with chemotherapy2

Survival2

Histology3

Completely resected3

Progression2

Combination1

Cell1

Adult and pediatric patients1

Clinical trials4

ESCC1

Metastases2

Histologies1

Immunotherapy4

Benefit2

Adjuvant chemotherapy1

Locally advanced disease1